Showing Results for
- Academic Journals (67)
Search Results
- 67
Academic Journals
- 67
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedChemoCentryx (Mountain View, CA, USA) has named Joseph M. Feczko to its board of directors. He was senior vice president and chief medical officer of Pfizer, where he worked from 1982 until his retirement in May 2009....
- 2From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedOn March 12, the US Food and Drug Administration (FDA) approved a cell-based treatment for gum recession developed by Canton, Massachusetts-based Organogenesis. Dubbed Gintuit, the cell therapy was the FDA's first...
- 3From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedTo the Editor: A news story in the March issue (1) notes the announcement by Ludwigshafen am Rhein, Germany-based agrochemical company BASF of a discontinuation of its breeding efforts for genetically modified (GM)...
- 4From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedInsurance claims could flag risks posed by some products, according to the first study of its kind conducted at the US Food and Drug Administration (FDA). Agency scientists collaborated with Wilmington, Delaware- based...
- 5From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedNat. Biotechnol. 30, 203 (2012); published online 7 March 2012; corrected after print 7 June 2012 In the version of this article initially published online, Craig Thompson was incorrectly identified as the president...
- 6From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedRay W. Miller (left) has been named as chief business officer of privately held industrial biotech company Verdezyne (Carlsbad, CA, USA). He served at DuPont for almost 40 years, with his most recent position being...
- 7From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedTo the Editor: 'Triple-stack' corn hybrids containing genetically engineered traits conferring resistance to major lepidopteran and coleopteran insect pests and to the herbicide glyphosate (Roundup; Monsanto, St....
- 8From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedApproaches for assessing misfolding during therapeutic protein production are needed because such changes can expose potentially reactive epitopes, which can result in dangerous side effects. Antibodies to detect subtle...
- 9From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedCarol Reed has been appointed senior vice president of clinical and regulatory affairs at Synthetic Biologics (Ann Arbor, MI, USA). She brings more than 25 years of experience in medical practice and in the...
- 10From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedThe results from a human trial of a nanoparticlebased cancer drug developed by BIND Biosciences of Cambridge, Massachusetts, provide positive evidence for the progress of a new generation of nanomedicines in the clinic....
- 11From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedThe success of any researcher turned entrepreneur depends, in large part, on their vision, leadership, intelligence, charisma and people skills. The 6-foot-5-inch frame of George Rathmann contained all of these...
- 12From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedThe Indian government and a UK charity are setting up an independent, not-for-profit company to fund the development of drugs and vaccines that specifically address diseases of major public health importance in India....
- 13From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedThe ability to engineer structures of protein complexes and to design interactions of high affinity and specificity would have countless applications in biology, medicine and public health. With the advent of...
- 14From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedWhen moving a new technology from the academic research laboratory into industry, life-sciences companies often also require an entirely new set of leadership-development skills. Leaders learn these skills not in the...
- 15From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedIn January, over 50 researchers from 30 academic and commercial organizations agreed on a standard for describing data sets. The BioSharing initiative, comprising both researchers and publishers, launched the...
- 16From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedTo increase the affinity of a protein-protein interaction, a tried-and-true strategy is to mutate the amino-acid residues that make up the binding interface and screen for mutants that bind more tightly. In practice,...
- 17From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedHugo Y K Lam, Michael J Clark, Rui Chen, Rong Chen, Georges Natsoulis, Maeve O'Huallachain, Frederick E Dewey, Lukas Habegger, Euan A Ashley, Mark B Gerstein, Atul J Butte, Hanlee P Ji & Michael Snyder Nat....
- 18From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedNo medical tests are currently available to predict when an arterial plaque is at an imminent risk of rupturing and causing a heart attack or stroke. In a retrospective human clinical study of 50 heart attack cases and...
- 19From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedThe discovery of human embryonic stem cells (hESCs) in 1998 was hailed as the biggest scientific advance of the past millennium. Buried in the fine print at the end of his heralded Science paper that detailed the...
- 20From: Nature Biotechnology. (Vol. 30, Issue 6) Peer-ReviewedFoxtail millet (Setaria italica) is not only an important food and fodder crop in arid regions worldwide but also a close diploid relative of the polyploid lignocellulosic biofuel crop switchgrass (Panicum virgatum)....